Anti-Phospho-UBLE1A (SAE1) (Ser185)(U208-65R)

Anti-Phospho-UBLE1A (SAE1) (Ser185)(U208-65R)

  • $675.00


Description :Rabbit Polyclonal Antibody

Species :

Tag :

Expression System:

Sequence :

Specificity :Recognizes the human SUMO Activating Enzyme E1 protein

Cited Applications :ELISA, WB
Ideal working dilutions for each application should be empirically determined by the investigator.

Cross Reactivity :Human, Bovine, Mouse, Rat and Dog

Host Isotype / Clone# :Rabbit, IgG

Immunogen :The antibody was produced against synthesized peptide corresponding to a region surrounding Serine185 of the human SUMO Activating Enzyme E1 protein

Purification :Affinity chromatography

Stability :1yr at –20oC from date of shipment.

Sample Data :Western blot using Anti-Phospho-UBlE1A (SAE1) (Ser185) antibody (2 µg/mL). Left lane (-) contains 20 µg human HeLa whole cell protein. Right lane (+) contains 20 µg human HeLa whole cell protein from cells pre-treated with phosphatase inhibitor cocktail to prevent dephos-phorylation of the target.

Scientific Background :UBLE1A (also known as SAE1) or SUMO1 activating enzyme subunit 1 is involved in regulating protein structure and intracellular localization. SAE1 and UBA2 form a heterodimer that functions as a SUMO-activating enzyme for the sumoylation of proteins (1). The SAE1/SAE2 dimer functions in SUMO1 activation in a manner analogous to the single E1 ubiquitin-activating enzymes. The SAE2 inactivation may be a therapeutic strategy in MYC-driven cancers (2).

References :
1. Okuma, T. In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun. 254: 693-698, 1999.

2. Kessler, J. D. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 369: 348-353, 2012.

Product Sheets (By Lot #) :


Research Areas :Angiogenesis, Apoptosis/Autophagy, Cancer, Cell Cycle, Cellular Stress, Inflammation, Invasion/Metastasis, Neurobiology